- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/52 - Purines, e.g. adenine
Patent holdings for IPC class A61K 31/52
Total number of patents in this class: 2858
10-year publication summary
|
196
|
196
|
179
|
187
|
179
|
147
|
167
|
151
|
164
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10511 |
48 |
| The Regents of the University of California | 20315 |
44 |
| Gilead Sciences, Inc. | 2112 |
30 |
| Infinity Pharmaceuticals, Inc. | 99 |
28 |
| Merck Sharp & Dohme LLC | 3737 |
28 |
| Boehringer Ingelheim International GmbH | 4596 |
25 |
| Merck Sharp & Dohme Corp. | 2187 |
24 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2918 |
24 |
| Signal Pharmaceuticals, LLC | 181 |
23 |
| K36 Therapeutics, Inc. | 26 |
23 |
| Dana-Farber Cancer Institute, Inc. | 2621 |
22 |
| F. Hoffmann-La Roche AG | 7895 |
21 |
| Epizyme, Inc. | 371 |
21 |
| Amgen Inc. | 4278 |
20 |
| The Johns Hopkins University | 5764 |
20 |
| AstraZeneca AB | 2834 |
19 |
| Centre National de La Recherche Scientifique | 10726 |
19 |
| Intellikine LLC | 41 |
18 |
| Rhizen Pharmaceuticals AG | 55 |
18 |
| Incyte Corporation | 1032 |
17 |
| Other owners | 2366 |